"Growing Adoption of Personalized Biologic Therapies"
- The Still’s disease treatment market is witnessing a shift toward personalized biologic therapies, leveraging advanced biomarkers and genetic profiling to tailor IL-1 and IL-6 inhibitors like anakinra, canakinumab, and tocilizumab to individual patient profiles.
- This approach optimizes dosing, minimizes side effects, and improves remission rates by targeting specific inflammatory pathways based on ferritin levels, cytokine profiles, and genetic predispositions. The trend aligns with the rising demand for precision medicine in autoimmune disorders, enhancing outcomes in both pediatric (SJIA) and adult (AOSD) populations. Integration of AI-driven diagnostic tools is further refining treatment plans, enabling real-time monitoring of inflammatory markers.
- For instance, in February 2025, a U.S.-based rheumatology consortium reported that biomarker-guided canakinumab dosing reduced flare rates by 70% in SJIA patients with elevated IL-1β, compared to standard protocols, in a multicenter study.
- The growing adoption of personalized biologic therapies, supported by biomarkers and AI diagnostics, is transforming Still’s disease treatment , enhancing efficacy and aligning with precision medicine trends to propel market growth.
